Anxo Pharmaceutical Co., Ltd. (TPEX:6677)

Anxo Pharmaceutical Revenue

Anxo Pharmaceutical had revenue of 438.39M TWD in the half year ending June 30, 2026, with 5.67% growth. This brings the company's total for the last twelve months to 878.88M, down -0.49% year-over-year. In the year 2025, Anxo Pharmaceutical had annual revenue of 843.26M, down -5.81%. That makes Anxo Pharmaceutical the 32,024th largest company in the world by revenue and 1,648th in Taiwan.

• Revenue (ttm): 878.88M
• Revenue Growth: -0.49%
• P/S Ratio: 1.21
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 1.06B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Development of Western Medicine and Marketing Department 826.42M 66.9%
• Western Medicine Manufacturing Department 408.03M 33.1%

By Geography

Chart

• Taiwan 648.88M 76.9%
• Europe 119.98M 14.2%
• China 57.39M 6.8%
• Others 9.34M 1.1%
• Singapore 6.74M 0.8%
• Japan 940.00K 0.1%

Fiscal year ended Dec 31, 2025 See the full Anxo Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	843.26M	-52.06M	-5.81%
Dec 31, 2024	895.32M	-44.62M	-4.75%
Dec 31, 2023	939.94M	73.67M	8.50%
Dec 31, 2022	866.27M	42.17M	5.12%
Dec 31, 2021	824.10M	-42.01M	-4.85%

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 17, 2026

Data Sources Report a data error